Monodox
(Doxycycline Monohydrate)ApprovedSmall molecule
Monodox is one of 6 small molecule programs targeting Lip. It is currently in Approved.
1
Indications
16
Total Trials
1
Active Trials
5
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
6 competitors in Lip
#DrugCompanyPhaseTrials
1Monodox
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Berberine
XXijing Hospital of Digestive Diseases
Phase 3
Octreotide
Johnson & JohnsonPhase 1
Adrenaline
SSamson Clinical Operations Pty Ltd
Phase 1
Isopto Carpine
AAdvanz Pharma
Preclinical
Vyxeos
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fasting Conditions5 trials
Fed3 trials
Proliferative Diabetic Retinopathy1 trial
4 more indications
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
VIBRAMYCIN
NDA NDA050006
Jan 1, 1982
VIBRAMYCIN
NDA NDA050480
Feb 10, 1992
MONODOX
NDA NDA050641
May 26, 2006
ORACEA
NDA NDA050805
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Doxycycline Monohydrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details